June 2020- Volume 16, Issue 6

In this Issue

Discovery

Further success in malaria initiative

Further success in malaria initiative

Optibrium and Intellegens report in-vitro validation of in-silico-generated compound

Know your enemy

Know your enemy

Team uses knowledge of how SARS-CoV-2 infects cells to identify drugs that could combat it

Managing macrolactones

Managing macrolactones

New database could aid large-molecule drug discovery and research

Complementary cancer collaboration

Complementary cancer collaboration

Exscientia and SRI combine strengths for oncology drug discovery

Relying on RNAi

Relying on RNAi

Vir and Alnylam identify RNAi development candidate targeting SARS-CoV-2

Arrakis partners with Roche

Arrakis partners with Roche

Collaboration will use RNA-targeted small-molecule discovery platform for multiple targets

Commentary

Testing, testing, testing...1,2,3,4

Testing, testing, testing...1,2,3,4

Diagnostic testing is hotter news right now with COVID than perhaps ever before, but what does it all mean?

Guest Commentary: Accelerating the pace of pharma innovation at a molecular level

Guest Commentary: Accelerating the pace of pharma innovation at a molecular level

Innovation isn’t just measured in the number of approvals, and looking at NMEs might be a better gauge of the ways in which drug discovery is currently thriving

Special Reports

Editor's Focus

Editor’s Focus: Cancer, COVID and change

Editor’s Focus: Cancer, COVID and change

Editor’s Focus: Cancer, COVID and change

Change is the name of the game in our understanding of cancer, the effect of COVID and the future of DDN magazine

Clinical Trials

Investigating an IL-6 antibody

Investigating an IL-6 antibody

An update on Sanofi and Regeneron’s Kevzara trial in hospitalized COVID-19 patients

Usher update

Usher update

ProQR offers upbeat interim analysis in Phase 1/2 trial of QR-421a for Usher Syndrome

Well-tolerated tumor drug

Well-tolerated tumor drug

Antibody therapeutic from Compugen demonstrates no dose-limiting toxicities

Optimal OPTICs

Optimal OPTICs

ADVM-022 demonstrates efficacy, durability in OPTIC trial in wet AMD

More skin in the game

More skin in the game

Libtayo shows promise for a second indication

Contract Services

Making a deal on ADCs

Making a deal on ADCs

Trio Pharmaceuticals and Ajinomoto enter into development collaboration

A strong complement in China

A strong complement in China

Reaction Biology, PharmaCore Labs strike up collaboration agreement

Preclinical

Data recommend RECCE 327

Data recommend RECCE 327

Synthetic antibiotic shows efficacy against priority antibiotic-resistant pathogen

An autoimmune option

An autoimmune option

Immutep and Batavia Biosciences reach LAG-3 immunotherapy milestone

Negative Data Prize is a positive?

Negative Data Prize is a positive?

Global Preclinical Data Forum says sharing negative science results is key to neuroscience progress

Feature

Focus Feature on Cancer Research News

Focus Feature on Cancer Research News

Recent happenings on the R&D front to better understand cancer and create oncology therapeutics

Diagnostics

A better test for COVID-19

A better test for COVID-19

Digital PCR solution cuts down on false negatives, may help in clinical trials

Against antibiotic resistance

Against antibiotic resistance

Selux Diagnostics receives additional 9.6 million for rapid AST platform

Putting the ‘AI’ in diagnostics

Putting the ‘AI’ in diagnostics

A look at the growing trend of integrating artificial intelligence and machine learning with diagnostics

Business & Government Policy

Broadening its footprint in biotech

Broadening its footprint in biotech

Germany’s Sartorius acquires selected assets of Danaher Life Sciences

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Q&A: The challenges of a vaccine for COVID-19

Q&A: The challenges of a vaccine for COVID-19

DDN takes some time to speak with Amélie Boulais, vaccine platform marketing manager at Sartorius Stedim Biotech

Research & Development

Meaningful biomarkers

Meaningful biomarkers

Precision medicine analyses show potential for Alzheimer’s drug

AUM launches Knockdown Coronavirus

AUM launches Knockdown Coronavirus

RNA could be the kryptonite to defeat COVID-19

Building a biobank

Building a biobank

Biogen, Broad Institute and Partners HealthCare create consortium for COVID-19 efforts

Timing is everything

Timing is everything

Suppression of immune system may be key to reducing COVID-19 severity
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 16 • Issue 10 • November 2020

November 2020

November 2020 Issue